Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06872112 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
A Phase 1 study of Pulmonary Arterial Hypertension PAH, sponsored by Joseph C. Wu.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06872112: Recruiting Phase 1 study of Pulmonary Arterial Hypertension PAH, sponsored by Joseph C. Wu.
NCT06872112 is a Phase 1 study of Pulmonary Arterial Hypertension PAH that is actively recruiting participants, run by Joseph C. Wu. The registered enrollment target is 15 participants, below the 45-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06872112, a Phase 1 study of Pulmonary Arterial Hypertension PAH, is actively recruiting participants, sponsored by Joseph C. Wu.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.
Conditions Studied
Interventions
- DRUG Artesunate
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 1 |
What NCT06872112 shows while recruiting
NCT06872112 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 45-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Pulmonary Arterial Hypertension PAH appearing as the primary indexed condition, and to 1 intervention - of which Artesunate is the first listed.
NCT06872112 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06872112 about?
NCT06872112 is a clinical study titled "A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension". This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.
What is the current status of trial NCT06872112?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-01-01. Estimated completion is 2029-01-01.
What conditions does trial NCT06872112 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension PAH.
What interventions are being tested in trial NCT06872112?
The interventions under investigation include: Artesunate (DRUG).
Who is sponsoring clinical trial NCT06872112?
This trial is sponsored by Joseph C. Wu, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06872112 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension PAH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Intravenous ZMA001 in Healthy Subjects
RECRUITING · Phase 1
-
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy
COMPLETED · Phase 1
-
Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension
RECRUITING · NA
-
PAH Exercise Study
RECRUITING · Phase 3
-
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI